{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:00:02Z","timestamp":1793228402659,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.lanepe.2025.101569","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T06:59:05Z","timestamp":1767596345000},"page":"101569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Management of Parkinson's disease psychosis\u2014a European perspective"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9729-9728","authenticated-orcid":false,"given":"Walter","family":"Pirker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Poewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.lanepe.2025.101569_bib1","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"16","year":"2017","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.lanepe.2025.101569_bib2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","year":"2018","journal-title":"Lancet Neurol"},{"issue":"s1","key":"10.1016\/j.lanepe.2025.101569_bib3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JPD-181474","article-title":"The emerging evidence of the Parkinson pandemic","volume":"8","author":"Dorsey","year":"2018","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.lanepe.2025.101569_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101569_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.parkreldis.2007.05.009","article-title":"A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia","volume":"14","author":"McKinlay","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101569_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.14802\/jmd.14019","article-title":"Neuropsychiatric symptoms in Parkinson's disease dementia are associated with increased caregiver burden","volume":"8","author":"Oh","year":"2015","journal-title":"J Mov Disord"},{"issue":"4","key":"10.1016\/j.lanepe.2025.101569_bib7","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1212\/WNL.45.4.669","article-title":"Mortality and hallucinations in nursing home patients with advanced Parkinson's disease","volume":"45","author":"Goetz","year":"1995","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.lanepe.2025.101569_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/14656566.2024.2316135","article-title":"Parkinson's disease psychosis management: an evidence based, experience informed, pragmatic approach","volume":"25","author":"Friedman","year":"2024","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.lanepe.2025.101569_bib9","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.lanepe.2025.101569_bib10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/14656566.2025.2481205","article-title":"Management of Parkinson's disease psychosis: first-line antipsychotic selection and rationale for continuing, combining, or switching","volume":"26","author":"Isaacson","year":"2025","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101569_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/01.wnl.0000191325.31068.c4","article-title":"Hallucinations in Parkinson disease in the prelevodopa era","volume":"66","author":"Fenelon","year":"2006","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.lanepe.2025.101569_bib12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(05)70146-0","article-title":"Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study","volume":"4","author":"Williams","year":"2005","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.lanepe.2025.101569_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrneurol.2016.200","article-title":"The psychosis spectrum in Parkinson disease","volume":"13","author":"Ffytche","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"Pt 4","key":"10.1016\/j.lanepe.2025.101569_bib14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","article-title":"Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors","volume":"123","author":"Fenelon","year":"2000","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.lanepe.2025.101569_bib15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101569_bib16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3233\/JPD-212930","article-title":"Frequency and characteristics of psychosis in Parkinson's disease: a systematic review and meta-analysis","volume":"12","author":"Chendo","year":"2022","journal-title":"J Parkinsons Dis"},{"issue":"8","key":"10.1016\/j.lanepe.2025.101569_bib17","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","article-title":"Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group","volume":"22","author":"Ravina","year":"2007","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.lanepe.2025.101569_bib18","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1212\/01.WNL.0000157058.17871.7B","article-title":"Acute akinesia in Parkinson disease","volume":"64","author":"Onofrj","year":"2005","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.lanepe.2025.101569_bib19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/jnnp.64.4.533","article-title":"Auditory hallucinations in Parkinson's disease","volume":"64","author":"Inzelberg","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8497","key":"10.1016\/j.lanepe.2025.101569_bib20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(86)92576-6","article-title":"At the receiving end of the lisuride pump","volume":"2","author":"Todes","year":"1986","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.lanepe.2025.101569_bib21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.parkreldis.2010.06.010","article-title":"Isolated delusional syndrome in Parkinson's disease","volume":"16","author":"Stefanis","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 6","key":"10.1016\/j.lanepe.2025.101569_bib22","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1002\/mds.10567","article-title":"Psychosis in Parkinson's disease","volume":"18","author":"Poewe","year":"2003","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.lanepe.2025.101569_bib23","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00702-019-01980-7","article-title":"Management of delirium in Parkinson's disease","volume":"126","author":"Ebersbach","year":"2019","journal-title":"J Neural Transm"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101569_bib24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up","volume":"75","author":"Pollak","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.lanepe.2025.101569_bib25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41582-023-00918-8","article-title":"Parkinson disease psychosis: from phenomenology to neurobiological mechanisms","volume":"20","author":"Pagonabarraga","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"10.1016\/j.lanepe.2025.101569_bib26","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00415-005-0918-5","article-title":"Psychotic symptoms in Parkinson's disease. From description to etiology","volume":"252","author":"Papapetropoulos","year":"2005","journal-title":"J Neurol"},{"issue":"10\u201311","key":"10.1016\/j.lanepe.2025.101569_bib27","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00702-004-0209-9","article-title":"Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease","volume":"111","author":"Merims","year":"2004","journal-title":"J Neural Transm"},{"key":"10.1016\/j.lanepe.2025.101569_bib28","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.lanepe.2025.101569_bib30","doi-asserted-by":"crossref","first-page":"1068722","DOI":"10.1155\/padi\/1068722","article-title":"Clozapine for quetiapine-refractory psychosis in Parkinson\u2019s disease: a long-term single-center retrospective study","author":"Pirker","year":"2025","journal-title":"Parkinsons Dis"},{"issue":"10","key":"10.1016\/j.lanepe.2025.101569_bib31","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease","volume":"340","year":"1999","journal-title":"N Engl J Med"},{"issue":"9169","key":"10.1016\/j.lanepe.2025.101569_bib32","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","article-title":"Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group","volume":"353","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101569_bib33","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2024.1816","article-title":"The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force","volume":"68","author":"Verdoux","year":"2025","journal-title":"Eur Psychiatry"},{"issue":"3","key":"10.1016\/j.lanepe.2025.101569_bib34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/JCP.0000000000001990","article-title":"Letter to the FDA proposing major changes in the US clozapine package insert supported by clozapine experts worldwide. Part II: a review of fatal outcomes in US pharmacovigilance data and proposed changes","volume":"45","author":"de Leon","year":"2025","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.lanepe.2025.101569_bib35","first-page":"1","article-title":"Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis","author":"Wagner","year":"2025","journal-title":"Br J Psychiatry"},{"issue":"4","key":"10.1016\/j.lanepe.2025.101569_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2217\/nmt.15.27","article-title":"Managing psychosis in Parkinson's disease without drugs","volume":"5","author":"Wand","year":"2015","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101569_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jamaneurol.2018.2820","article-title":"Patterns of dementia treatment and frank prescribing errors in older adults with Parkinson disease","volume":"76","author":"Mantri","year":"2019","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.lanepe.2025.101569_bib38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jalz.2012.02.005","article-title":"Long-term anticholinergic use and the aging brain","volume":"9","author":"Cai","year":"2013","journal-title":"Alzheimer's Dement"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101569_bib39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12877-018-0929-6","article-title":"An anticholinergic burden score for German prescribers: score development","volume":"18","author":"Kiesel","year":"2018","journal-title":"BMC Geriatr"},{"issue":"3","key":"10.1016\/j.lanepe.2025.101569_bib44","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1176\/jnp.12.3.364","article-title":"Clozapine and risperidone treatment of psychosis in Parkinson's disease","volume":"12","author":"Ellis","year":"2000","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"8","key":"10.1016\/j.lanepe.2025.101569_bib71","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","article-title":"Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease","volume":"20","author":"Ondo","year":"2005","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.lanepe.2025.101569_bib72","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.21116","article-title":"Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration","volume":"22","author":"Rabey","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.lanepe.2025.101569_bib73","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/NDT.S5335","article-title":"A randomized controlled trial of quetiapine for psychosis in Parkinson's disease","volume":"5","author":"Shotbolt","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101569_bib74","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.10374","article-title":"Long-term outcome of quetiapine use for psychosis among Parkinsonian patients","volume":"18","author":"Fernandez","year":"2003","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.lanepe.2025.101569_bib75","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","article-title":"Quetiapine and clozapine in Parkinsonian patients with dopaminergic psychosis","volume":"27","author":"Morgante","year":"2004","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"10.1016\/j.lanepe.2025.101569_bib76","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.WNF.0000236769.31279.19","article-title":"Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis","volume":"29","author":"Merims","year":"2006","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101569_bib40","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0006-3223(02)01392-6","article-title":"Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease","volume":"52","author":"Breier","year":"2002","journal-title":"Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101569_bib41","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/mds.10217","article-title":"Olanzapine treatment for dopaminergic-induced hallucinations","volume":"17","author":"Ondo","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.lanepe.2025.101569_bib42","doi-asserted-by":"crossref","first-page":"150","DOI":"10.12688\/f1000research.2-150.v1","article-title":"A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease","volume":"2","author":"Nichols","year":"2013","journal-title":"F1000Res"},{"issue":"4","key":"10.1016\/j.lanepe.2025.101569_bib80","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson'S disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"9916","key":"10.1016\/j.lanepe.2025.101569_bib79","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"issue":"Suppl 4","key":"10.1016\/j.lanepe.2025.101569_bib51","first-page":"S1","article-title":"Management of Parkinson's disease: an evidence-based review","volume":"17","author":"Goetz","year":"2002","journal-title":"Mov Disord"},{"issue":"Suppl 3","key":"10.1016\/j.lanepe.2025.101569_bib52","first-page":"S42","article-title":"The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease","volume":"26","author":"Seppi","year":"2011","journal-title":"Mov Disord"},{"issue":"6","key":"10.1016\/j.lanepe.2025.101569_bib43","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.55.6.789","article-title":"Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients","volume":"55","author":"Goetz","year":"2000","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.lanepe.2025.101569_bib45","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/mds.24942","article-title":"Melperone is ineffective in treating Parkinson's disease psychosis","volume":"27","author":"Friedman","year":"2012","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101569_bib46","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/JPD-181448","article-title":"A systematic review and case series of ziprasidone for psychosis in Parkinson's disease","volume":"9","author":"Younce","year":"2019","journal-title":"J Parkinsons Dis"},{"issue":"12","key":"10.1016\/j.lanepe.2025.101569_bib47","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/mds.21091","article-title":"Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease","volume":"21","author":"Friedman","year":"2006","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.lanepe.2025.101569_bib48","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/npr2.12235","article-title":"Safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease-results of a multicenter open trial","volume":"42","author":"Kashihara","year":"2022","journal-title":"Neuropsychopharmacol Rep"},{"key":"10.1016\/j.lanepe.2025.101569_bib49","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.parkreldis.2019.11.013","article-title":"Severe parkinsonism caused by brexpiprazole: a case report","volume":"69","author":"Jackowiak","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"10.1016\/j.lanepe.2025.101569_bib53","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/mds.870130302","article-title":"Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience","volume":"13","author":"Trosch","year":"1998","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.lanepe.2025.101569_bib54","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1212\/WNL.48.3.658","article-title":"Low-dose clozapine improves dyskinesias in Parkinson's disease","volume":"48","author":"Durif","year":"1997","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.lanepe.2025.101569_bib55","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1017\/S1121189X00000427","article-title":"The role of psychopharmacology in suicide prevention","volume":"18","author":"Saunders","year":"2009","journal-title":"Epidemiol Psichiatr Soc"},{"issue":"11","key":"10.1016\/j.lanepe.2025.101569_bib57","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s00277-020-04215-y","article-title":"Clozapine-induced agranulocytosis","volume":"99","author":"Mijovic","year":"2020","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.lanepe.2025.101569_bib58","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/mdc3.13582","article-title":"Clozapine is severely underused in Parkinson's disease patients","volume":"9","author":"Friedman","year":"2022","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"10.1016\/j.lanepe.2025.101569_bib59","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/JCP.0000000000001556","article-title":"Clozapine rechallenge or continuation despite neutropenia, an extended follow-up of a consecutive Quebec case series","volume":"42","author":"Bechard","year":"2022","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101569_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2215-0366(23)00343-7","article-title":"Evaluating the epidemiology of clozapine-associated neutropenia among people on clozapine across Australia and Aotearoa New Zealand: a retrospective cohort study","volume":"11","author":"Northwood","year":"2024","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"10.1016\/j.lanepe.2025.101569_bib63","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/JCP.0000000000001927","article-title":"Myocarditis on clozapine 50 mg\/d in a patient with Parkinson's disease","volume":"44","author":"Skoble","year":"2024","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101569_bib64","first-page":"19","article-title":"Repeated occurrence of clozapine-induced myocarditis in a patient with schizoaffective disorder and comorbid Parkinson's disease","volume":"30","author":"Masopust","year":"2009","journal-title":"Neuroendocrinol Lett"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101569_bib65","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2042098618756261","article-title":"Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine","volume":"9","author":"De Berardis","year":"2018","journal-title":"Ther Adv Drug Saf"},{"issue":"9","key":"10.1016\/j.lanepe.2025.101569_bib66","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1177\/02698811211021587","article-title":"Unravelling cases of clozapine-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in patients reported otherwise: a systematic review","volume":"35","author":"de Filippis","year":"2021","journal-title":"J Psychopharmacol"},{"issue":"4","key":"10.1016\/j.lanepe.2025.101569_bib67","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/20009666.2019.1627848","article-title":"Clozapine associated pulmonary embolism: systematic review","volume":"9","author":"Poudyal","year":"2019","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"1\u20132","key":"10.1016\/j.lanepe.2025.101569_bib68","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jns.2008.04.026","article-title":"Weight change in Parkinson and Alzheimer patients taking atypical antipsychotic drugs","volume":"272","author":"Sitburana","year":"2008","journal-title":"J Neurol Sci"},{"issue":"7","key":"10.1016\/j.lanepe.2025.101569_bib69","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/ijnp\/pyac005","article-title":"Incidence of drug-induced delirium during treatment with antidepressants or antipsychotics: a drug surveillance report of german-speaking countries between 1993 and 2016","volume":"25","author":"Friedrich","year":"2022","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.lanepe.2025.101569_bib70","series-title":"Stahl's Essential Psychopharmacology","author":"Stahl","year":"2021"},{"key":"10.1016\/j.lanepe.2025.101569_bib77","article-title":"Impact of pimavanserin on prescribing practices in Parkinson disease","volume":"12","author":"Pham Nguyen","year":"2025","journal-title":"Clin Park Relat Disord"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101569_bib78","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1212\/WNL.58.1.160-a","article-title":"Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease","volume":"58","author":"Brandstadter","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.lanepe.2025.101569_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105951","article-title":"Pimavanserin for psychosis in Parkinson's disease dementia: subgroup analysis of the HARMONY Trial","volume":"119","author":"Weintraub","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.lanepe.2025.101569_bib82","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.parkreldis.2020.07.021","article-title":"Efficacy and safety of atypical antipsychotics for psychosis in Parkinson's disease: a systematic review and Bayesian network meta-analysis","volume":"78","author":"Iketani","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.lanepe.2025.101569_bib83","article-title":"Long-term outcomes with pimavanserin for psychosis in clinical practice","volume":"6","author":"Akbar","year":"2022","journal-title":"Clin Park Relat Disord"},{"key":"10.1016\/j.lanepe.2025.101569_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105356","article-title":"Clozapine: efficacy for Parkinson disease psychosis in patients refractory to pimavanserin","volume":"109","author":"Thames","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"issue":"24","key":"10.1016\/j.lanepe.2025.101569_bib85","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson's disease","volume":"351","author":"Emre","year":"2004","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.lanepe.2025.101569_bib86","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jamaneurol.2023.1835","article-title":"Cholinesterase inhibitors for treatment of psychotic symptoms in Alzheimer disease and Parkinson disease: a meta-analysis","volume":"80","author":"d'Angremont","year":"2023","journal-title":"JAMA Neurol"},{"issue":"14","key":"10.1016\/j.lanepe.2025.101569_bib87","doi-asserted-by":"crossref","first-page":"e1539","DOI":"10.1212\/WNL.0000000000009214","article-title":"Seeing ophthalmologic problems in Parkinson disease: results of a visual impairment questionnaire","volume":"94","author":"Borm","year":"2020","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.lanepe.2025.101569_bib88","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mds.10450","article-title":"Coping strategies for visual hallucinations in Parkinson's disease","volume":"18","author":"Diederich","year":"2003","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.lanepe.2025.101569_bib89","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/mdc3.70056","article-title":"Using principles of cognitive behavioral therapy to treat anxiety in Parkinson's disease","volume":"12","author":"Cronin-Golomb","year":"2025","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101569_bib90","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/mds.28335","article-title":"Electroconvulsive therapy for Parkinson's disease: a systematic review and meta-analysis","volume":"36","author":"Takamiya","year":"2021","journal-title":"Mov Disord"},{"issue":"8","key":"10.1016\/j.lanepe.2025.101569_bib91","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.3390\/brainsci13081193","article-title":"Novel compounds in the treatment of schizophrenia-a selective review","volume":"13","author":"Tsapakis","year":"2023","journal-title":"Brain Sci"},{"issue":"4","key":"10.1016\/j.lanepe.2025.101569_bib92","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200175","article-title":"Ulotaront, a trace amine-associated receptor 1\/serotonin 5-HT(1A) agonist, in patients with Parkinson disease psychosis: a pilot study","volume":"13","author":"Isaacson","year":"2023","journal-title":"Neurol Clin Pract"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776225003618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776225003618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:20:28Z","timestamp":1785363628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776225003618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":87,"alternative-id":["S2666776225003618"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2025.101569","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Parkinson's disease psychosis\u2014a European perspective","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2025.101569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101569"}}